CY1121106T1 - Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της - Google Patents

Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της

Info

Publication number
CY1121106T1
CY1121106T1 CY191100028T CY191100028T CY1121106T1 CY 1121106 T1 CY1121106 T1 CY 1121106T1 CY 191100028 T CY191100028 T CY 191100028T CY 191100028 T CY191100028 T CY 191100028T CY 1121106 T1 CY1121106 T1 CY 1121106T1
Authority
CY
Cyprus
Prior art keywords
quetiapine
production
product
fatty acid
acid conjugates
Prior art date
Application number
CY191100028T
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Sanjib Bera
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CY1121106T1 publication Critical patent/CY1121106T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα τεχνολογία παρέχει μια νέα κατηγορία προφαρμάκων της κουετιαπίνης που μπορούν να συντεθούν με χημική σύζευξη λιπαρών οξέων στην κουετιαπίνη. Παρέχονται επίσης φαρμακευτικές συνθέσεις και μέθοδοι σύνθεσης συζευγμάτων της παρούσας τεχνολογίας. Επιπλέον, παρέχονται μέθοδοι θεραπείας των ασθενών με τις συνθέσεις της παρούσας τεχνολογίας.
CY191100028T 2010-03-11 2019-01-14 Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της CY1121106T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31297710P 2010-03-11 2010-03-11
PCT/US2011/027658 WO2011112657A1 (en) 2010-03-11 2011-03-09 Fatty acid conjugates of quetiapine, process for making and using the same

Publications (1)

Publication Number Publication Date
CY1121106T1 true CY1121106T1 (el) 2019-12-11

Family

ID=44560214

Family Applications (1)

Application Number Title Priority Date Filing Date
CY191100028T CY1121106T1 (el) 2010-03-11 2019-01-14 Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της

Country Status (14)

Country Link
US (7) US20110223207A1 (el)
EP (2) EP2544536B1 (el)
CY (1) CY1121106T1 (el)
DK (1) DK2544536T3 (el)
ES (1) ES2705233T3 (el)
HR (1) HRP20190057T1 (el)
HU (1) HUE042945T2 (el)
LT (1) LT2544536T (el)
PL (1) PL2544536T3 (el)
PT (1) PT2544536T (el)
RS (1) RS58335B1 (el)
SI (1) SI2544536T1 (el)
TR (1) TR201900067T4 (el)
WO (1) WO2011112657A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061250B2 (en) * 2009-06-26 2015-06-23 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
CA2889457C (en) 2009-12-31 2016-06-28 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN103097008B (zh) 2010-09-15 2015-12-09 Bl科技公司 围绕可溶芯体制造纱增强式中空纤维膜的方法
CN103747788A (zh) * 2011-05-13 2014-04-23 马尼托巴大学 用喹硫平或其类似物治疗暴露于uv辐射的皮肤
US9321014B2 (en) * 2011-12-16 2016-04-26 Bl Technologies, Inc. Hollow fiber membrane with compatible reinforcements
US9643129B2 (en) 2011-12-22 2017-05-09 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9022229B2 (en) 2012-03-09 2015-05-05 General Electric Company Composite membrane with compatible support filaments
US8999454B2 (en) 2012-03-22 2015-04-07 General Electric Company Device and process for producing a reinforced hollow fibre membrane
JP6286429B2 (ja) 2012-08-21 2018-02-28 ヤンセン ファーマシューティカ エヌ．ベー． パリペリドンのハプテン
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
ES2691092T3 (es) 2012-08-21 2018-11-23 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
PL2888286T3 (pl) * 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
EP3354751B1 (en) 2012-08-21 2019-10-02 Janssen Pharmaceutica NV Antibodies to aripiprazole and use thereof
WO2014031656A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
ES2822907T3 (es) * 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de quetiapina para su uso en inmunoensayos
CN108640996A (zh) 2012-08-21 2018-10-12 詹森药业有限公司 帕潘立酮的抗体及其用途
US9504682B2 (en) 2012-08-21 2016-11-29 Janssen Pharmaceutica Nv Haptens of aripiprazole
PL2888269T3 (pl) 2012-08-21 2019-06-28 Janssen Pharmaceutica Nv Hapteny olanzapiny
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
PL2888263T3 (pl) 2012-08-21 2018-10-31 Janssen Pharmaceutica Nv Hapteny rysperydonu i paliperydonu
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
US9227362B2 (en) 2012-08-23 2016-01-05 General Electric Company Braid welding
WO2014057439A2 (en) * 2012-10-13 2014-04-17 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
EA201591137A1 (ru) 2013-03-15 2016-02-29 Селджен Авиломикс Рисерч, Инк. Ингибиторы mk2 и их применения
MA44067A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
CN109689598A (zh) * 2016-07-27 2019-04-26 陶氏环球技术有限责任公司 可交联的表面活性剂
WO2018045094A1 (en) * 2016-08-31 2018-03-08 The Board Of Trustees Of The Leland Stanford Junior University Ladderane lipid compounds and liposomes and methods of preparing and using the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064138A (en) 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
DE69320378T2 (de) 1992-01-21 1999-04-29 Macrochem Corp Iontophoretische verbesserte Verabreichung von Medikamenten
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US20070225379A1 (en) 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
IL160306A0 (en) * 2001-08-31 2004-07-25 Univ Rockefeller Method for classification of anti-psychotic drugs
ES2379544T3 (es) 2001-09-27 2012-04-27 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina y GABA y usos del mismo
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7393920B2 (en) * 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
WO2005002586A1 (en) 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
WO2005002587A1 (en) 2003-07-02 2005-01-13 Astrazeneca Ab Quetiapine metabolite with antipsychotic activity
JP2007509155A (ja) * 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
CA2596023A1 (en) * 2005-01-27 2006-11-09 Ocean Nutrition Canada Ltd. Fatty acid-benzenediol derivatives and methods of making and using thereof
WO2007004236A2 (en) 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2008050341A2 (en) 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
CN101616585A (zh) 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
CA2889457C (en) 2009-12-31 2016-06-28 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same

Also Published As

Publication number Publication date
US20130158007A1 (en) 2013-06-20
ES2705233T3 (es) 2019-03-22
US20130045247A1 (en) 2013-02-21
US20150044261A1 (en) 2015-02-12
EP2544536A4 (en) 2013-08-14
WO2011112657A1 (en) 2011-09-15
PT2544536T (pt) 2019-01-23
US20170246301A1 (en) 2017-08-31
DK2544536T3 (en) 2019-02-04
PL2544536T3 (pl) 2019-05-31
TR201900067T4 (tr) 2019-02-21
US20170247368A1 (en) 2017-08-31
HRP20190057T1 (hr) 2019-03-22
LT2544536T (lt) 2019-02-25
EP3476218A1 (en) 2019-05-01
HUE042945T2 (hu) 2019-07-29
US8900604B2 (en) 2014-12-02
EP2544536A1 (en) 2013-01-16
US9889198B2 (en) 2018-02-13
US20110223207A1 (en) 2011-09-15
US9511149B2 (en) 2016-12-06
SI2544536T1 (sl) 2019-03-29
RS58335B1 (sr) 2019-03-29
US9890150B2 (en) 2018-02-13
EP2544536B1 (en) 2018-12-12
US20170042906A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
CY1121106T1 (el) Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
MX2019001093A (es) Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
BR112013028534A2 (pt) compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
MY158504A (en) Fatty acid niacin conjugates and their uses
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
EA201390934A1 (ru) Композиции и способы модулирования fxr
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
MX368966B (es) Conjugados de proteina-polimero-farmaco.
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BR112012000569B8 (pt) composição compreendendo um conjugado de benzoato-hidrocodona (bz-hc) e composições para administração oral e intravenosa compreendendo o mesmo
MX362857B (es) Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
EP2536736A4 (en) PREPARATION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATE PRODUCTS THEREOF
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
GT201300025A (es) Derivados anticancerosos, su preparación y su aplicación en terapeútica
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CY1117416T1 (el) Παραγωγα βενζαζολης ως προσδετες του υποδοχεα ισταμινης η4
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
BR112012022109A2 (pt) derivados de aminoindanos, seu preparo e sua aplicação em produtos terapêuticos